TheEdgeResearch
Home / Stocks / MRNA

Moderna, Inc. (MRNA)

NASDAQ Healthcare Biotechnology
$170.50 ▲ +10.69%
Market Cap
$67.65B
Sector
Healthcare
Industry
Biotechnology
Beta
0.90
52-Wk Range
22.28-176.66
CEO
Stéphane Bancel
Country
US
Currency
USD

Moderna, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $170.50, up 10.69% on the session, giving a market capitalisation of $67.65B. On trailing twelve-month figures it carries a trailing P/E of -21.37, a net margin of -141.4%. Its beta of 0.90 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-21.37
Price / Sales
30.36
Price / Book
9.99
EV / EBITDA
-23.76
Gross margin
-12.6%
Operating margin
-149.0%
Net margin
-141.4%
Return on equity
Debt / equity
0.19
Current ratio
2.29
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
4,700
IPO date
2018-12-07
Headquarters
Cambridge, MA, US
About Moderna, Inc.

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

Comparable companies

Moderna, Inc. is most often compared with the following Healthcare names:

BBIOBMRNCAIEXELHALOJAZZMDGLRNARVMDTECH
More research on MRNA
MRNA technical analysis MRNA TheEdge Score Compare against peers
Open full interactive analysis & DCF →